glp-1 receptor agonist and dpp-4 inhibitor combination not recommended inhibitors GLP-1RAs: cardiovascular safety and benefits | Military Medical Research GLP-1 receptor agonists vs. DPP-4

Avraham SA, Hossein J, Somri F, Hawash N, Hochman O

Curr Med Res Opin 2016;32:251262 [DOI] [PubMed] [Google Scholar] 50.Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE

In short, the drugs trigger insulin release, reduce glucose production in your liver and make you feel full, according to GoodRx

doi: 10.1111/dom.12596 94 GlaesnerWVickAMMillicanREllisBTschangSHTianYet al

GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art

Compared with exenatide, lixisenatide is generally well tolerated, with a lower incidence of hypoglycemia, lower immune response at the injection site, and less side effects such as nausea and vomiting